MedDataX Logo

Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.

NCT ID: NCT00773123

Last Updated: 2008-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-10-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RT-View utilizes spectral domain technology to assess both RNFL and ganglion cell layer thickness. This study aims to correlate visual field defects in patients with glaucoma to both RNFL and ganglion cell layer thickness.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

RT-View Spectral domain OCT Ganglion cell layer RNFL Visual field defect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Primary open angle glaucoma

No interventions assigned to this group

2

Normal controls

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Evidence of retinal disease
* Neovascular glaucoma
* Secondary glaucoma due to intraocular inflammation
* Lens induced glaucoma
* Tumor induced glaucoma
Minimum Eligible Age

10 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chan Yun Kim, MD,PhD

Role: CONTACT

Phone: 82-2-2228-3570

Email: [email protected]

Sung Yong Kang, MD

Role: CONTACT

Phone: 82-2-2228-3570

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chan Yun Kim, MD,PhD

Role: primary

Sung Yong Kang, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

08-0342

Identifier Type: -

Identifier Source: org_study_id